| scholarly article | Q13442814 |
| P50 | author | Michael S. Torbenson | Q106615136 |
| P2093 | author name string | Young H Ko | |
| Peter L Pedersen | |||
| Jean-Francois H Geschwind | |||
| Carolyn Magee | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cancer | Q623031 |
| P304 | page(s) | 3909-3913 | |
| P577 | publication date | 2002-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production | |
| P478 | volume | 62 |
| Q38946644 | 3-Bromopyruvate induces rapid human prostate cancer cell death by affecting cell energy metabolism, GSH pool and the glyoxalase system. |
| Q34993713 | 3-Bromopyruvate inhibits human gastric cancer tumor growth in nude mice via the inhibition of glycolysis |
| Q37980697 | 3-bromopyruvate: Targets and outcomes |
| Q36372328 | A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
| Q92082272 | ATP Synthase Subunit Epsilon Overexpression Promotes Metastasis by Modulating AMPK Signaling to Induce Epithelial-to-Mesenchymal Transition and Is a Poor Prognostic Marker in Colorectal Cancer Patients |
| Q37158312 | Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. |
| Q47604904 | An essential role for IGF2 in cartilage development and glucose metabolism during postnatal long bone growth. |
| Q41947562 | Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization |
| Q36693454 | Angiotensin II increases gene expression after selective intra-arterial adenovirus delivery in a rabbit model assessed using in vivo SSTR2-based reporter imaging |
| Q64067410 | Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells |
| Q35111997 | Assessment of Tumoricidal Efficacy and Response to Treatment with18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor |
| Q44908249 | Best supportive care of hepatocellular carcinoma |
| Q35075838 | C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia |
| Q43066128 | Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. |
| Q55317070 | Cancer and Exercise: Warburg Hypothesis, Tumour Metabolism and High-Intensity Anaerobic Exercise. |
| Q27013632 | Cancer cell metabolism: implications for therapeutic targets |
| Q34509607 | Cellular ATP Synthesis Mediated by Type III Sodium-dependent Phosphate Transporter Pit-1 Is Critical to Chondrogenesis |
| Q39262718 | Citrate kills tumor cells through activation of apical caspases |
| Q28480562 | Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis |
| Q41317851 | Comparison of two different methods for inoculating VX2 tumors in rabbit livers and hind limbs. |
| Q36577658 | Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells |
| Q28079559 | Drugging the addict: non-oncogene addiction as a target for cancer therapy |
| Q39542687 | Dynamic scenario of metabolic pathway adaptation in tumors and therapeutic approach |
| Q36342034 | EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3‐bromopyruvate |
| Q38863836 | Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells. |
| Q39398652 | Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase |
| Q36512795 | Effective Elimination of Cancer Stem Cells By a Novel Drug Combination Strategy |
| Q35052021 | Emerging metabolic targets in cancer therapy |
| Q37063643 | FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model |
| Q39399488 | Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis |
| Q38042261 | Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma |
| Q39490136 | Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. |
| Q34722614 | Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. |
| Q36377949 | Hepatocellular carcinoma: therapy and prevention |
| Q33880100 | Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells |
| Q24595940 | Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria |
| Q64093565 | Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma |
| Q46501130 | Impaired mitochondrial functions contribute to 3-bromopyruvate toxicity in primary rat and mouse hepatocytes. |
| Q37921677 | Inhibitors of succinate: quinone reductase/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death. |
| Q37627652 | Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer |
| Q41681638 | Intra-arterial Targeted Islet-specific Expression of Sirt1 Protects β Cells From Streptozotocin-induced Apoptosis in Mice |
| Q89995159 | Intracellular ATP levels influence cell fates in Dictyostelium discoideum differentiation |
| Q34432306 | Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism |
| Q35987880 | Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer |
| Q35213377 | Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis |
| Q26795759 | Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication |
| Q35506699 | Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B |
| Q36733720 | Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. |
| Q37431693 | Mitochondria and cancer |
| Q39491915 | Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells. |
| Q28548517 | Nanomicellar Formulation of Clotrimazole Improves Its Antitumor Action toward Human Breast Cancer Cells |
| Q28534587 | New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells |
| Q34769352 | Noninvasive Assessment of Gene Transfer and Expression by In Vivo Functional and Morphologic Imaging in a Rabbit Tumor Model |
| Q35801521 | PPARγ contributes to PKM2 and HK2 expression in fatty liver |
| Q35167406 | Perfusion CT Assessment of Tissue Hemodynamics Following Hepatic Arterial Infusion of Increasing Doses of Angiotensin II in a Rabbit Liver Tumor Model |
| Q38542150 | Pheochromocytoma: Gasping for Air. |
| Q46013875 | Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. |
| Q39445595 | Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy |
| Q24618782 | Purinergic signalling and cancer |
| Q38165746 | Purinergic signalling in the liver in health and disease |
| Q34672595 | Rabbit hepatic arterial anatomy variations: implications on experimental design. |
| Q39907305 | Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA. |
| Q26852150 | Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study |
| Q41587732 | Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma |
| Q39972485 | Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. |
| Q34834980 | Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model |
| Q38946885 | Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer |
| Q37983497 | Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug |
| Q36687966 | Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond? |
| Q39418495 | Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin |
| Q37384240 | Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study |
| Q37461264 | The Genome-Wide Expression Profile of l,2,3,4,6-Penta-O-Galloyl-β-D-Glucose-Treated MDA-MB-231 Breast Cancer Cells: Molecular Target on Cancer Metabolism |
| Q33846541 | The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. |
| Q34580081 | The Warburg effect and its cancer therapeutic implications |
| Q27025749 | The Warburg effect revisited--lesson from the Sertoli cell |
| Q38837920 | The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. |
| Q37406500 | The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. |
| Q34607831 | The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil |
| Q28296259 | The cancer cell's "power plants" as promising therapeutic targets: an overview |
| Q39648449 | The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma |
| Q26997789 | The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer |
| Q48560205 | The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria |
| Q39858276 | The isatin-Schiff base copper(II) complex Cu(isaepy)2 acts as delocalized lipophilic cation, yields widespread mitochondrial oxidative damage and induces AMP-activated protein kinase-dependent apoptosis |
| Q38039421 | The scarlet letter of alkylation: a mini review of selective alkylating agents. |
| Q62663288 | Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae |
| Q37436821 | Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate |
| Q64055907 | Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment |
| Q38168262 | Tumor glycolysis as a target for cancer therapy: progress and prospects |
| Q34185914 | Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model. |
| Q37225440 | Uncovering the role of VDAC in the regulation of cell life and death |
| Q28249524 | Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen |
| Q88139059 | [Monocarboxylate transporter 1 enhances the sensitivity of breast cancer cells to 3-bromopyruvate in vitro] |
Search more.